immuno-oncology

News

Scotland backs Cabometyx combo for kidney cancer, amid stall...

Patients in Scotland with newly-diagnosed advanced kidney cancer can now access a therapy combining Bristol-Myers Squibb's immunotherapy Opdivo with Ipsen's targeted drug Cabometyx, ahead o

News

FDA halts Allogene CAR-T trial after safety scare

A phase 1 trial of Allogene's of-the-shelf CAR-T for lymphoma has been placed on hold by the FDA, after a "chromosomal abnormality" was seen in a patient receiving the cell therapy.

News

Janssen J&J Johnson and Johnson pharmaceutical companies

J&J bulks up in bispecifics with $1.3bn Xencor alliance

Fresh from claiming its first bispecific antibody approval, Johnson & Johnson has delved deeper into the category with a deal to license a drug for B-cell cancers developed by Xencor.

Events